http://bmj.com/cgi/content/full/325/7357/180/a
| Home | Help | Search/Archive | Feedback | Table of Contents |
|
|||||||||
 Collections under
which this article appears: Cancer:
gynecological Menopause
(incl HRT) Drugs:
endocrine system |
Women taking oestrogen only hormone replacement therapy (HRT) for 10 years or more face a 60% greater risk of developing ovarian cancer than if they had never taken it, a new study shows (JAMA 2002;288:334-41)[Medline].
The study follows recent research implicating HRT in small increased risks of
cardiovascular disease, breast and uterine cancers, blood clots, and
stroke. HRT is used by an estimated 13.5 million women in the United
States
nearly eight
million take oestrogen only pills and around six million take the
combined oestrogen and progestogen form.
Dr James Lacey and colleagues from the US National Cancer Institute's Division of Epidemiology tracked the health of 44241 postmenopausal women, who were initially enrolled in the prospective breast cancer detection demonstration project, a breast cancer screening programme conducted in 29 sites across the United States from 1973 to 1980.
The researchers collected monitoring data, including information on type and length of HRT, age at first use, and development of any subsequent cancer, from 1978 to 1998. The data were collected through telephone interviews and questionnaires and covered 31354 women.
Until 1986 there was no attempt to distinguish oestrogen alone from oestrogen plus progestogen treatments, but subsequently this information was collected, including the number of days in the month the treatments were used. After 1993 information on names of drugs and doses was also collected.
Women in whom menopause was surgically induced, such as women who had had a hysterectomy, were included in the study if they had at least one ovary. Women who had had a bilateral oophorectomy or had ovarian or breast cancers before follow up were excluded.
Overall 329 women developed ovarian cancer during the monitoring period. Their average age at the start of the study was 56.6 years.
Compared with no use of HRT, use of oestrogen only HRT was associated with an increased risk of ovarian cancer, and this risk increased over time (rate ratio 1.6 (95% confidence interval 1.2 to 2.0).
The rate ratio was 1.8 (1.1 to 3.0) for 10-19 years of use and 3.2 (1.7 to 5.7) for 20 or more years (P value for trend <0.001). Furthermore, the rate ratio increased by 7% (2% to 13%) for every year of use.
The rate ratio for use of oestrogen plus progestogen HRT was 1.1 (0.64 to 1.7). Switching to this form of HRT after previous oestrogen only use did not completely eliminate the previous risk, conferring a rate ratio of 1.5 (0.91 to 2.4).
|
|||||||||
|
Collections under
which this article appears:Cancer:
gynecological Menopause
(incl HRT) Drugs:
endocrine system |
Read all Rapid Responses
| Home | Help | Search/Archive | Feedback | Table of Contents |
ALL INFORMATION, DATA, AND
MATERIAL CONTAINED, PRESENTED, OR PROVIDED HERE IS FOR GENERAL INFORMATION
PURPOSES ONLY AND IS NOT TO BE CONSTRUED AS REFLECTING THE KNOWLEDGE OR OPINIONS
OF THE PUBLISHER, AND IS NOT TO BE CONSTRUED OR INTENDED AS PROVIDING MEDICAL OR
LEGAL ADVICE. THE DECISION WHETHER OR NOT TO VACCINATE IS AN IMPORTANT AND
COMPLEX ISSUE AND SHOULD BE MADE BY YOU, AND YOU ALONE, IN CONSULTATION WITH
YOUR HEALTH CARE PROVIDER.